Deal facts
- Buyer
- MedPal AI plc
- Target
- Solid State Technologies Ltd
- Deal value
- GBP 474,000
- Announced
- 20 July 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United Kingdom
- Consideration
- cash, shares
Sources
MedPal AI plc has agreed to acquire Solid State Technologies Ltd in a strategic acquisition valued at £474,000. The transaction, announced on 20 July 2026, involves a combination of cash and shares as the primary consideration for the deal. Both the acquiring entity and the target company are headquartered in the United Kingdom, indicating a domestic transaction within the healthcare sector. This arrangement represents a significant step for MedPal AI plc in expanding its operational footprint and capabilities within the domestic healthcare market. The structure of the deal suggests a focus on integrating Solid State Technologies Ltd’s assets and expertise into the broader strategic framework of the buyer. The headline offer value reflects the agreed terms between the parties, providing a clear financial baseline for the acquisition.
The transaction is currently at the firm intention stage, with no completion date yet established. Regulatory approvals and other customary closing conditions will need to be satisfied before the deal can proceed to completion. Stakeholders are awaiting further updates regarding the timeline for finalising the agreement and integrating the target business. The combination of cash and share consideration indicates a balanced approach to financing the acquisition, aligning the interests of both parties. This deal marks a notable development in the UK healthcare sector, highlighting ongoing consolidation and strategic growth initiatives among industry participants. The outcome will depend on successful negotiation of final terms and timely regulatory clearance.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- Firm intention
Acquisition of eMARx
Disclaimer* 20 July 2026 MedPal AI plc ("MedPal", the "Company" or the "Group") Acquisition of eMARx: the digital medication layer for the UK care home market Completes MedPal's Health OS across the care home sector and opens a national roll-out from the Group's robotic dispensing hub MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-native digital health and pharmacy group, is
LSE RNS
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Cronos Group Inc. to acquire CanAdelaar B.V.
Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…
- Buyer
- Cronos Group Inc.
- Target
- CanAdelaar B.V.
- Deal value
- EUR 57,500,000
- Deal type
- strategic acquisition
Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.
Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…
- Buyer
- Alaunos Therapeutics, Inc.
- Target
- Velaris Therapeutics, Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
STERIS Corporation to acquire Xodus Medical, Inc.
STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…
- Buyer
- STERIS Corporation
- Target
- Xodus Medical, Inc.
- Deal value
- USD 2,100,000,000
- Deal type
- strategic acquisition
Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC
Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…
- Buyer
- Hepion Pharmaceuticals, Inc.
- Target
- Gravitas Life Sciences, LLC
- Deal value
- USD 4,250,000
- Deal type
- strategic acquisition
Buyer history
MedPal AI plc
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive